Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Baseline and Post-Bortezomib gene expression profiling of CD138 purified bone marrow plasma cells from multiple myeloma patients


ABSTRACT: High PSMD4 expression levels in plasma cells are linked to poor prognosis in multiple myeloma. Additional file available-E-TABM-1138.additional.zip

ORGANISM(S): Homo sapiens

SUBMITTER: Pingping Qu 

PROVIDER: E-TABM-1138 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.

Shaughnessy John D JD   Qu Pingping P   Usmani Saad S   Heuck Christoph J CJ   Zhang Qing Q   Zhou Yiming Y   Tian Erming E   Hanamura Ichiro I   van Rhee Frits F   Anaissie Elias E   Epstein Joshua J   Nair Bijay B   Stephens Owen O   Williams Ryan R   Waheed Sarah S   Alsayed Yazan Y   Crowley John J   Barlogie Bart B  

Blood 20110531 13


Gene expression profiling (GEP) of purified plasma cells 48 hours after thalidomide and dexamethasone test doses showed these agents' mechanisms of action and provided prognostic information for untreated myeloma patients on Total Therapy 2 (TT2). Bortezomib was added in Total Therapy 3 (TT3), and 48 hours after bortezomib GEP analysis identified 80 highly survival-discriminatory genes in a training set of 142 TT3A patients that were validated in 128 patients receiving TT3B. The 80-gene GEP mode  ...[more]

Similar Datasets

2017-02-23 | E-MTAB-5212 | biostudies-arrayexpress
2011-12-31 | E-TABM-1111 | biostudies-arrayexpress
2015-01-31 | E-MTAB-2441 | biostudies-arrayexpress
2011-04-08 | E-TABM-1091 | biostudies-arrayexpress
2011-12-16 | E-GEOD-16659 | biostudies-arrayexpress
2012-04-21 | E-TABM-1147 | biostudies-arrayexpress
2011-06-04 | E-GEOD-29712 | biostudies-arrayexpress
2010-01-14 | E-GEOD-19882 | biostudies-arrayexpress